{"id":"layla-tab","safety":{"commonSideEffects":[{"rate":"2-5%","effect":"Edema"},{"rate":"2-5%","effect":"Dizziness"},{"rate":"2-5%","effect":"Fatigue"},{"rate":"2-5%","effect":"Headache"},{"rate":"2-5%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL4542707","moleculeType":"Unknown","molecularWeight":"204.22"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The calcium channel blocker component, verapamil, works by relaxing the muscles in the heart and blood vessels, allowing blood to flow more easily and reducing blood pressure. The beta blocker component, atenolol, works by blocking the effects of the hormone epinephrine, also known as adrenaline, which can increase heart rate and blood pressure. By combining these two mechanisms, Layla Tab is able to provide effective blood pressure control and reduce the risk of heart-related complications.","oneSentence":"Layla Tab is a combination of two medications, a calcium channel blocker and a beta blocker, which work together to lower blood pressure and reduce the workload on the heart.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:41:00.351Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Angina pectoris"}]},"trialDetails":[{"nctId":"NCT07203547","phase":"PHASE4","title":"Phase 4 Study of Laybon Tab. in Knee Osteoarthritis","status":"NOT_YET_RECRUITING","sponsor":"Mather's Pharm. Co., Ltd.","startDate":"2025-12","conditions":"Osteoarthritis, Knee, Osteoarthritis","enrollment":172},{"nctId":"NCT02049606","phase":"PHASE4","title":"To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients of the Knee","status":"COMPLETED","sponsor":"PMG Pharm Co., Ltd","startDate":"2014-02-24","conditions":"Osteoarthritis of the Knee","enrollment":134},{"nctId":"NCT01768468","phase":"PHASE4","title":"To Compare the Efficacy and Safety of LAYLA in Osteoarthritis Patients","status":"COMPLETED","sponsor":"PMG Pharm Co., Ltd","startDate":"2012-10","conditions":"Osteoarthritis of the Knee","enrollment":124}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Layla Tab.","genericName":"Layla Tab.","companyName":"Mather's Pharm. Co., Ltd.","companyId":"mather-s-pharm-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Layla Tab is a combination of two medications, a calcium channel blocker and a beta blocker, which work together to lower blood pressure and reduce the workload on the heart. Used for Hypertension, Angina pectoris.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}